AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Bydureon (exenatide), a weekly type 2 diabetes GLP-1 class injection, is nearing the end of its patent life and is also under threat from Novo Nordisk’s next-generation weekly jab, semaglutide.

Of the 37.1 million patients with type 2 diabetes, 810,390 were new semaglutide users, 326,282 were treated with dulaglutide, 25,936 with exenatide (Byetta, Bydureon), 715,802 with empagliflozin ...

We update our list of Peroxide codes whenever there are new drops, so remember to bookmark this page and visit it for the latest goodies whenever you need help! PC Invasion is supported by our ...